Staging Fibrosis in Chronic Viral Hepatitis.

Area of Science:

• Hepatology
• Gastroenterology
• Biomarker Research

Background:

• Accurate liver fibrosis staging is challenging in viral hepatitis.
• Liver biopsy, the gold standard, has limitations including safety, cost, and interobserver variability.
• Non-invasive tests are increasingly adopted for fibrosis staging.

Purpose of the Study:

• To review non-invasive markers for staging liver fibrosis in chronic hepatitis B and C.
• To highlight the utility of serological and physical non-invasive tests.
• To address the gap in evaluating liver fibrosis after hepatitis C virus (HCV) cure.

Main Methods:

• Review of published data on liver fibrosis staging in viral hepatitis.
• Emphasis on non-invasive serological biomarkers.
• Inclusion of physical non-invasive testing methods.

Main Results:

• Non-invasive tests, including serological and physical markers, demonstrate reasonable accuracy for fibrosis staging.
• These methods are increasingly integrated into clinical practice for viral hepatitis.
• A significant knowledge gap exists regarding fibrosis evaluation post-HCV cure.

Conclusions:

• Non-invasive markers are valuable tools for liver fibrosis staging in viral hepatitis, complementing or replacing liver biopsy.
• Further research is needed to establish reliable methods for assessing liver fibrosis after HCV eradication.